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Dear Editor,
Hepatitis Monthly has recently published an interest-
ing and practically valuable original report from Yilmaz, 
et al. (1). That was a retrospective study investigating the 
ability of the aspartate transaminase to platelet ratio in-
dex (APRI) in diagnosing and predicting the extent of fi-
brosis in patients with chronic hepatitis B (CHB), chronic 
hepatitis C (CHC), and non-alcoholic fatty liver disease 
(NAFLD). This relatively large scale study was conducted 
on a cohort of 207 CHB patients, 108 CHC patients, and 
140 NAFLD patients. The results of that study were appar-
ently reliable and potentially useful with clinical signifi-
cance. The authors, by comparing with the results from 
liver biopsy, concluded that APRI has an acceptable ac-
curacy for the assessment of the extent of liver fibrosis 
in patients with CHC and NAFLD, but not in those with 
CHB.
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Various types of hepatitis, as well as fatty liver disease, 
have increasingly become an immense problem in both 
developed and developing countries across the world, 
which create heavy medical and social burdens. Patients 
with the said conditions may possess a pathological spec-
trum of fibrosis, cirrhosis, and ultimately liver cancer. 
Thus, the information on predicting and staging liver 
fibrosis is essential for prognostication and decisions on 
treating patients with chronic liver diseases. Liver biopsy 
is currently the gold standard for the assessment of liver 
histology. However, it is invasive and does carry an inneg-
ligible risk of complications. Moreover, it could be costly 
especially to the patients from developing countries. 
Hence, there is a need to develop an equally-accurate, 
reliable, noninvasive and inexpensive means to assess 
liver fibrosis. In the year 2003, Wai, et al. proposed APRI 
on the basis of routinely available laboratory test results, 
which were proven to have high sensitivity and specific-
ity in predicting liver fibrosis in patients with CHC. The 
data were published in Hepatology (2). Several studies 
in this field have further revealed the usefulness of APRI 
in patients with CHC, and a recent systematic review   Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co  All right reserved.Hepat Mon. 2011;11(5):376-377
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concludes that the major strength of the APRI is the ex-
clusion of significant HCV-related fibrosis (3). However, 
the information on the APRI in predicting fibrosis in 
patients with NAFLD and CHB is still lacking. This study 
has not only confirmed the results in patients with CHC, 
but also identified the role of APRI in patients with NA-
FLD and CHB. Furthermore, most of the previous studies 
on APRI were conducted in the Western countries, while 
Yusuf, et al., performed this study in an Asian population. 
Although other measures such as the Fibro test may un-
doubtedly achieve a rather similar result, their expense 
may preclude their actual application in non-wealthy pa-
tients. The impact and significant of this study are thus 
obvious. However, it could be a disadvantage of APRI in 
the future clinical usage that the upper limits of nor-
mal (ULNs) of aspartate transaminase could neither be 
standardized nor reproducible in different laboratories, 
which ought to be resolved in further studies.
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